|Bid||3.9800 x 900|
|Ask||4.0700 x 1000|
|Day's Range||3.9200 - 4.0700|
|52 Week Range||2.9100 - 7.6500|
|Beta (5Y Monthly)||2.27|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The CEO of Wayne-based Aevi is taking over as CEO of the combined company focused on rare pediatric diseases.
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
By David Bautz, PhD NASDAQ:CERC READ THE FULL CERC RESEARCH REPORT Business Update Acquisition of Aevi Genomic Medicine Strengthens Rare and Orphan Disease Pipeline On December 5, 2019, Cerecor, Inc. (NASDAQ:CERC) announced the acquisition of Aevi Genomic Medicine (GNMX) in an all-stock transaction valued at approximately $16.1 million plus contingent value rights (CVRs) for up to an additional
While small-cap stocks, such as Cerecor Inc. (NASDAQ:CERC) with its market cap of US$191m, are popular for their...
By David Bautz, PhD NASDAQ:CERC READ THE FULL CERC RESEARCH REPORT Business Update CDG FIRST Trial Underway On July 15, 2019, Cerecor Inc. (NASDAQ:CERC) announced the first patient has been enrolled in ...
The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...
On April 29, 2019, Cerecor Inc. (CERC) announced dosing has completed in the Phase 1 clinical trial of CERC-801 (D-galactose), which is being developed for the treatment of Phosphoglucomutase 1 (PGM1) deficiency. The open label, randomized, single dose, 4-way crossover study in 16 healthy adult volunteers showed CERC-801 to be safe and well tolerated with no reports of serious adverse events. The company has also initiated a natural history study to collect efficacy and safety data from CDG patients treated with monosaccharide replacement therapy, which will be an important part of the application for approval using the 505(b)(2) pathway.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Vanguard founder Jack Bogle helped spearhead the low-cost index fund, putting average returns w...
The Phase 1 trial is a double blind, randomized, placebo controlled trial with a target enrollment of 20 Parkinson’s patients with nOH. Each patient will have five visits in which they will receive four single escalating doses of drug (8, 12, 16, or 20 mg) or placebo.
Cerecor, Inc. (CERC) is a fully integrated biopharmaceutical company with commercial operations intended to support the development of a pipeline of therapies targeting neurology, pediatric, and orphan indications. The neurology pipeline is led by CERC-301, which is currently in a Phase 1 clinical trial in patients with neurogenic orthostatic hypotenstion (nOH). Cerecor is currently conducting a Phase 1 clinical trial of its lead neurology candidate CERC-301 for the treatment of nOH associated with Parkinson’s disease and other neurodegenerative diseases.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Every investor in Cerecor Inc. (NASDAQ:CERC) should be aware ofRead More...